These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1119822)

  • 21. Cosmetic and dermatology: bleaching creams.
    Engasser PG; Maibach HI
    J Am Acad Dermatol; 1981 Aug; 5(2):143-7. PubMed ID: 7021611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of combination of glycolic acid peeling with topical regimen in treatment of melasma.
    Chaudhary S; Dayal S
    J Drugs Dermatol; 2013 Oct; 12(10):1149-53. PubMed ID: 24085051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Postinflammatory Hyperpigmentation With a Combination of Glycolic Acid Peels and a Topical Regimen in Dark-Skinned Patients: A Comparative Study.
    Sarkar R; Parmar NV; Kapoor S
    Dermatol Surg; 2017 Apr; 43(4):566-573. PubMed ID: 28114204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined therapy using Q-switched ruby laser and bleaching treatment with tretinoin and hydroquinone for periorbital skin hyperpigmentation in Asians.
    Momosawa A; Kurita M; Ozaki M; Miyamoto S; Kobayashi Y; Ban I; Harii K
    Plast Reconstr Surg; 2008 Jan; 121(1):282-288. PubMed ID: 18176232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma.
    Nanda S; Grover C; Reddy BS
    Dermatol Surg; 2004 Mar; 30(3):385-8; discussion 389. PubMed ID: 15008866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening.
    Draelos ZD; Yatskayer M; Bhushan P; Pillai S; Oresajo C
    Cutis; 2010 Sep; 86(3):153-8. PubMed ID: 21049734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Herndon JH; Sigler ML; Gotz V; Garruto J; Mehta RC
    J Drugs Dermatol; 2012 Dec; 11(12):1478-82. PubMed ID: 23377519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful treatment of hydroquinone-resistant melasma using topical methimazole.
    Malek J; Chedraoui A; Nikolic D; Barouti N; Ghosn S; Abbas O
    Dermatol Ther; 2013; 26(1):69-72. PubMed ID: 23384022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 4% hydroquinone versus 4% hydroquinone, 0.05% dexamethasone and 0.05% tretinoin in the treatment of melasma: a comparative study.
    Astaneh R; Farboud E; Nazemi MJ
    Int J Dermatol; 2005 Jul; 44(7):599-601. PubMed ID: 15985034
    [No Abstract]   [Full Text] [Related]  

  • 30. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation.
    Cook-Bolden FE; Hamilton SF
    Cutis; 2008 Apr; 81(4):365-71. PubMed ID: 18491487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical treatments for melasma and postinflammatory hyperpigmentation.
    Lynde CB; Kraft JN; Lynde CW
    Skin Therapy Lett; 2006 Nov; 11(9):1-6. PubMed ID: 17075653
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance and efficacy of a product containing ellagic and salicylic acids in reducing hyperpigmentation and dark spots in comparison with 4% hydroquinone.
    Dahl A; Yatskayer M; Raab S; Oresajo C
    J Drugs Dermatol; 2013 Jan; 12(1):52-8. PubMed ID: 23377328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depigmentation with tert-butyl hydroquinone using black guinea pigs.
    Patrick E; Juberg DR; O'Donoghue J; Maibach HI
    Food Chem Toxicol; 1999; 37(2-3):169-75. PubMed ID: 10227740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-n-butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation.
    Kolbe L; Mann T; Gerwat W; Batzer J; Ahlheit S; Scherner C; Wenck H; Stäb F
    J Eur Acad Dermatol Venereol; 2013 Jan; 27 Suppl 1():19-23. PubMed ID: 23205541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A microsponge formulation of hydroquinone 4% and retinol 0.15% in the treatment of melasma and postinflammatory hyperpigmentation.
    Grimes PE
    Cutis; 2004 Dec; 74(6):362-8. PubMed ID: 15663072
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy and safety of a multimodality skin brightener composition compared with 4% hydroquinone.
    Makino ET; Mehta RC; Garruto J; Gotz V; Sigler ML; Herndon JH
    J Drugs Dermatol; 2013 Mar; 12(3):s21-6. PubMed ID: 23545929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Methods and means for pigmentation and depigmentation. Sense or nonsense?].
    Hegyi V; Hegyi J
    Hautarzt; 2010 Jul; 61(7):586-92. PubMed ID: 20549480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Melasma. Etiologic and therapeutic considerations.
    Grimes PE
    Arch Dermatol; 1995 Dec; 131(12):1453-7. PubMed ID: 7492140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study.
    Burns RL; Prevost-Blank PL; Lawry MA; Lawry TB; Faria DT; Fivenson DP
    Dermatol Surg; 1997 Mar; 23(3):171-4; discussion 175. PubMed ID: 9145958
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of a pigmented lesion induced by a Pelagia noctiluca sting.
    Kokelj F; Burnett JW
    Cutis; 1990 Jul; 46(1):62-4. PubMed ID: 1974491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.